1. PO.1.12 Transcriptome profiling and autoimmunity-related serological markers identify TP53 and C3aR as drug targets in neuropsychiatric systemic lupus erythematosus. (27th September 2022) Authors: Lindblom, J; Toro-Domínguez, D; Carnero-Montoro, E; Borghi, MO; Castillo, J; Iacobaeus, E; Enman, Y; Repsilber, D; Mohan, C; Alarcón-Riquelme, M; Barturen, G; Parodis, I Journal: Lupus science & medicine Issue: Volume 9(2022)Supplement 2 Page Start: A29 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PO.1.21 Attainment of EQ-5D-3L full health state after therapy is associated with decelerated organ damage accrual in systemic lupus erythematosus. (27th September 2022) Authors: Lindblom, J; Zetterberg, S; Borg, A; Emamikia, S; Von Perner, G; Enman, Y; Heintz, E; Regardt, M; Grannas, D; Gomez, A; Parodis, I Journal: Lupus science & medicine Issue: Volume 9(2022)Supplement 2 Page Start: A33 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. PO.5.99 Drug repurposing for treating lupus nephritis based on transcriptome profiling and autoimmunity-related serological markers. (27th September 2022) Authors: Parodis, I; Lindblom, J; Toro-Domínguez, D; Carnero-Montoro, E; Borghi, MO; Castillo, J; Enman, Y; Repsilber, D; Mohan, C; Alarcón-Riquelme, M; Barturen, G Journal: Lupus science & medicine Issue: Volume 9(2022)Supplement 2 Page Start: A78 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. PO.7.146 Sensitivity analysis of EQ-5D-3L index scores in relation to discriminative and known-groups validity in systemic lupus erythematosus. (27th September 2022) Authors: Hua, N; Gomez, A; Lindblom, J; Von Perner, G; Enman, Y; Regardt, M; Heintz, E; Emamikia, S; Grannas, D; Parodis, I Journal: Lupus science & medicine Issue: Volume 9(2022)Supplement 2 Page Start: A109 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. PO.7.149 Associations between abnormal bmi and patient-reported health-related quality of life before and after therapeutic intervention in patients with systemic lupus erythematosus. (27th September 2022) Authors: Borg, A; Soltani, A; Emamikia, S; Lindblom, J; Gomez, A; Von Perner, G; Enman, Y; Heintz, E; Regardt, M; Grannas, D; Parodis, I Journal: Lupus science & medicine Issue: Volume 9(2022)Supplement 2 Page Start: A110 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. S04.2 Medication adherence in patients with systemic lupus erythematosus: results from a Swedish survey. (27th September 2022) Authors: Emamikia, S; Gomez Gonzalez, A; Ådahl, T; Von Perner, G; Enman, Y; Chatzidionysiou, K; Arkema, E; Parodis, I Journal: Lupus science & medicine Issue: Volume 9(2022)Supplement 2 Page Start: A7 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗